Individualising HbA1c Targets: Moving Beyond Glucocentrism in Type 2 Diabetes Care

Key Takeaways

• Rigid, uniform glycemic strategies create severe risks of hypoglycemia and treatment burdens in older, frail cohorts.
• The landmark UKPDS trial proves early, intensive glycemic control provides a lasting legacy effect for younger, newly diagnosed individuals.
• Clinical de-escalation thresholds provide precise guidelines to safely down-titrate high-risk diabetes medications based on frailty tiers.
• Discrepancies between home blood glucose readings and laboratory HbA 1c values warrant immediate clinical evaluation for underlying hematological or systemic conditions.
• Avoid Glucocentrism: Treat the individual sitting in front of you, not the laboratory number. Always investigate any clinical mismatch between a patient’s HbA 1c and home glucose readings.
• Age is just a number. Your clinical decisions must be guided primarily by the patient’s functional status, frailty tier, and personal treatment wishes.
• For older, frail populations, pivot away from strict glycemic control to prevent hypoglycemia, hypovolemia, and sarcopenia. Proactively utilize peer-reviewed de-escalation thresholds to safely down-titrate or stop unnecessary therapies.

Introduction

Managing Type 2 diabetes in modern primary care has evolved far beyond chasing a single, uniform laboratory metric. For years, institutional frameworks like the Quality and Outcomes Framework (QOF) inadvertently incentivized a “one size fits all” approach, tying practice metrics to rigid targets. However, clinical reality across the NHS demands a shifting perspective. Primary care teams face immense pressure to balance absolute numbers against the actual safety, frailty, and quality of life of individual patients.

To address these complex clinical paradigms, The Medicines Management Team (TMMT) recently organized an expert video upskilling lecture. The session was delivered by Dr. Kevin Fernando, a renowned Portfolio GP within NHS Lothian and Honorary Clinical Reader at the University of Dundee. Dr. Fernando challenged primary care clinicians including GPs, clinical pharmacists, and advanced nurse practitioners to reconsider the true goal of diabetes treatment.

Relying on the philosophy that we must treat the person rather than the number, this article unpacks the core clinical insights from the lecture, providing an interactive reference guide for practices looking to optimize their clinical pathways.

Dr Kevin Quoted Abraham Lincoln that “In the end, it’s not the years in your life that count. It’s the life in your years.” 

Pathophysiology: Why Hyperglycemia Matters 

There is no doubt that hyperglycemia is central to both microvascular and macrovascular disease. This risk spans a continuous spectrum; in individuals both with and without diagnosed diabetes, any elevated degree of hyperglycemia increases vascular risk.

Hyperglycemia is an independent risk factor for cardiovascular disease because chronic high blood glucose levels directly damage the vascular endothelium. This damage triggers:

1. Oxidative stress and the subsequent release of free radicals.
2. Low-grade inflammation within blood vessels.

Together, these processes accelerate plaque formation and atherosclerosis, directly leading to subsequent atherosclerotic cardiovascular disease (ASCVD), such as coronary heart disease and stroke.

However, historical data proves that we have been far too glucocentric in our approach to Type 2 diabetes care. This rigid mindset has partly been driven by institutional frameworks like the Quality and Outcomes Framework (QOF), which historically tied financial point attainment to rigid, uniform HbA 1c targets.

Instead, we must adopt a holistic, person-centered approach. We need to treat the person, not the number. This evokes another favorite quote of Dr Kevin from the late, great Canadian physician, Sir William Osler:

“The good physician treats the disease; the great physician treats the person who has the disease.”

This sentiment applies equally to physicians, pharmacists, and nurses today.

The Evidence Base: Rigid vs. Individualised Control 

Understanding how to safely apply the practice of individualising HbA 1c targets requires an objective examination of the historical clinical trials that shape modern diabetes guidelines. The evidence reveals a clear divide between younger, newly diagnosed cohorts and older, highly comorbid populations. 

The UKPDS Legacy Effect 

The findings were definitive. Tight glycemic control achieved a 25% absolute reduction in microvascular complications, such as retinopathy and neuropathy. Furthermore, the data showed that for every 1% absolute reduction in HbA 1c, there was a corresponding 21% reduction in diabetes-related mortality and a 14% reduction in myocardial infarctions. Crucially, a 44-year follow-up presented at the 2022 EASD Congress confirmed that this intensive early control creates a permanent “legacy effect,” protecting younger individuals from multi-decade vascular damage.

The ACCORD, ADVANCE, and VADT Triad

Conversely, trials conducted around 2008–2009; specifically ACCORD, ADVANCE, and VADT, evaluated a fundamentally different patient profile. These studies enrolled older individuals (typically over 65) with an established history of Type 2 diabetes spanning 10 to 20 years, alongside severe comorbidities like cardiovascular disease and chronic kidney disease (CKD).

When these trials attempted aggressive glycemic control targeting an HbA 1c of less than 6.0%, the results shifted. Tight control failed to provide macrovascular benefits. Most critically, the ACCORD trial was terminated early due to a shocking 22% increase in all-cause mortality within the intensive group. In older, vulnerable populations, aggressive glucose-lowering strategies cause direct, measurable harm.

Landmark Trial Comparison

A Pragmatic Guide to De-escalation Thresholds 

The lesson from these landmark trials is clear: Primum non-nocere (First, do no harm). As primary care workloads intensify, implementing structured HbA1c de-escalation thresholds offers a reliable mechanism to safeguard vulnerable patients from over-treatment, hypovolemia, falls, and sarcopenia (muscle loss).

The landmark UK Prospective Diabetes Study (UKPDS), published in the late 1990s, focused on a younger population ranging from ages 25 – 65 years with a mean age of 53, who were newly diagnosed with Type 2 diabetes. The intensive treatment arm aimed for a tight fasting plasma glucose of less than 6 mmol/L

Following the peer-reviewed framework published by David Strain and colleagues, diabetes management can be stratified across three distinct frailty tiers: 

Tier 1: Fit Older Adults

• Target HbA 1c: 58 mmol/mol
• De-escalation Action: If the HbA 1c drops below 53 mmol/mol, clinicians should actively evaluate the treatment regimen. High-risk therapies, particularly sulfonylureas and complex insulin regimens, should be down-titrated or simplified to mitigate the risk of severe hypoglycemic events.

Tier 2: Moderate to Severe Frailty

• Target HbA 1c: 64 mmol/mol
• De-escalation Action: If values drop below 48 mmol/mol, immediate de-escalation is required. Clinicians should discontinue or minimize high-risk agents, transitioning patients toward safer alternatives with negligible hypoglycemic footprints, such as DPP-4 inhibitors. Medications like pioglitazone must also be scrutinized due to associated risks of fluid retention, heart failure, and osteoporotic fractures.

Tier 3: Severe Frailty / End-of-Life Care

• Target HbA 1c: 70+ mmol/mol
• De-escalation Action: When a patient’s glycemic profile drops below 60 mmol/mol, the care model must pivot entirely toward comfort, immediate safety, and quality of life. Preventative therapies lacking short-term clinical utility, such as statins, should be stopped. Complex insulin regimens must be heavily reduced or ceased, as significant muscle loss reduces overall metabolic insulin requirements.

Clinical Exception Note: SGLT2 inhibitors represent a unique exception within moderate frailty cohorts. They should often be maintained or initiated independent of glycemic targets if the patient suffers from concurrent heart failure, as their organ-protective benefits manifest rapidly, often within 14 to 21 days. 

When the Numbers Lie: HbA 1c Invalidation 

A critical highlight of Dr. Fernando’s lecture was a warning regarding absolute laboratory data. Clinicians must maintain a healthy skepticism when a patient’s clinical presentation contradicts their laboratory results. 

The Case of Paul 

Consider the clinical profile of Paul, a 58-year-old gentleman diagnosed with Type 2 diabetes five years ago. He presented for his annual review with a body mass index (BMI) of 26 and an elevated waist-to-height ratio of 0.54 (where a healthy baseline is less than 0.50). His home blood pressure was stable at 129/79 mmHg, but his laboratory HbA 1c had abruptly climbed to 74 mmol/mol.

Paul expressed intense frustration, reporting that his home capillary blood glucose readings consistently averaged a stable 7 to 8 mmol/L in the mornings. He also noted unexplained weight loss. Rather than blindly intensifying his diabetes medications, an immediate full blood count and hematinics panel were ordered. The results revealed severe microcytic anemia (Hemoglobin: 79 g/L, Ferritin: 5 mcg/L). Paul was immediately fast-tracked via an urgent suspected cancer pathway, which ultimately uncovered a sigmoid colon cancer. His weight loss was due to malignancy, and his elevated HbA 1c was an artifact of severe iron deficiency.

Mechanics of Glycation Interference 

This case underscores how red blood cell (RBC) dynamics directly dictate HbA 1c validity:

• Artificial Elevation: In cases of chronic iron, Vitamin B12, or folate deficiencies, the lifespan of the red blood cell is prolonged. Because these cells circulate within the bloodstream longer than the typical 120 days, they undergo an extended duration of glycation, yielding an artificially inflated HbA 1c that misrepresents true average blood sugars.
• Artificial Suppression: Conversely, any condition that shortens RBC survival—including acute blood loss, hemolytic anemias, erythropoietin therapy, advanced CKD, hemodialysis, or recent blood transfusions leads to an artificially deflated HbA 1c.

When facing these clinical scenarios, primary care teams must utilize alternative monitoring modalities, such as quality-controlled laboratory plasma glucose profiles or fructosamine testing, which measures glycated serum proteins over a shorter, 2-to-4-week window independent of hemoglobin variations.

Conclusion

Successfully individualising HbA1c targets requires primary care teams to step away from uniform, metric-driven workflows and embrace person-centered, adaptive medicine. Balancing early, intensive control for younger patients against safe, structured de-escalation for frail cohorts protects patients from clinical over-treatment and hidden diagnostic pitfalls.

Optimizing these complex chronic care pathways requires consistent clinical focus. To learn more about how remote clinical pharmacists can support your practice workflows, explore the dedicated support options available through TMMT’s medicines management service page.

How TMMT Restructures Practice Capacity 

Systematically auditing patient lists, identifying frailty in diabetes care, and executing accurate HbA1c de-escalation thresholds requires significant clinical time and focus. For busy GP partners and PCN leads, finding the necessary capacity within standard operational boundaries can be exceptionally difficult.

This is where integrating dedicated medicines management services provides a clear operational advantage. Working alongside The Medicines Management Team (TMMT) gives practices access to a structured framework of remote clinical pharmacists and pharmacy technicians. Because TMMT provides an established operational workflow, practices can easily utilize their NHS Additional Roles Reimbursement Scheme (ARRS) funding without wasting administrative capacity.

Remote clinical pharmacists ARRS personnel can take ownership of these complex portfolios by running targeted audits to identify over-treated frail populations, systematically tracking diagnostic anomalies like Paul’s case, and adjusting treatment regimens safely. This clinical support unburdens the core practice workforce, ensuring full regulatory compliance while enhancing patient safety across the board.

FAQs